Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical (NYSE American: XTNT) announced an exclusive partnership with BioHorizons, a Henry Schein company, under which BioHorizons will distribute Xtant’s allogeneic growth factor technology as a private-label product named Prolifica™ through its commercial network.
The agreement designates BioHorizons as the exclusive distributor of Xtant’s allogeneic growth factor technology for dental and oral-maxillofacial procedures in the United States and Canada. According to Xtant Medical, the collaboration combines its regenerative medicine development and manufacturing capabilities with BioHorizons’ established commercial reach and clinician relationships, aiming to create a long-term channel for expanded access to Prolifica and a platform for continued joint initiatives.
Prolifica is described as a naturally occurring blend of allogeneic growth factors stabilized by native human collagen, processed to preserve a biphasic release of proteins to support bone healing and regeneration across multiple clinical applications. It is now available to clinicians via the BioHorizons commercial network.
Xtant Medical (NYSE American: XTNT) reported second quarter 2026 revenue of $23.0 million, down from $35.4 million a year earlier, mainly due to the December 2025 sale of its non-core Coflex/CoFix assets and international hardware business to Companion Spine and the end of high-margin license revenue tied to reimbursement changes.
Gross margin declined to 57.9% from 68.6%. Operating expenses rose to $22.5 million, driven largely by a $5.0 million exclusivity fee to Dilon Technologies related to a new U.S. distribution agreement for the HEMOBLAST Bellows hemostasis product. Xtant recorded a net loss of $9.4 million versus net income of $3.6 million in Q2 2025, and a non-GAAP adjusted EBITDA loss of $2.7 million versus positive $6.9 million.
As of June 30, 2026, Xtant held $9.9 million in cash and cash equivalents, total debt of $23.0 million, and $0.7 million in revolver availability. The company modestly lowered its 2026 revenue guidance to $99–$103 million, from $101–$105 million, citing softer biologics revenue and ongoing headwinds in its amnio product line.
Xtant Medical (NYSE American: XTNT) will release its second quarter 2026 financial results, for the period ended June 30, 2026, before the market opens on Tuesday, August 11, 2026. Management will host a conference call and live webcast at 8:30 AM ET to discuss the results. Dial-in numbers, passcode, and webcast link are provided, and a replay will be available on the company’s website under “Investor info.”
Xtant Medical (NYSE American: XTNT) announced that CEO Sean Browne, CFO Scott Neils and COO Mark Schallenberger will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, held August 11-13, 2026. The company’s presentation is scheduled for Tuesday, August 11 at 2:00 pm ET, with a live webcast and a replay available on its investor website for 90 days.
Xtant Medical (NYSE American: XTNT) reported first quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, with gross margin of 57.3% and operating expenses of $14.9 million. Net loss was $3.1 million and adjusted EBITDA loss was $1.6 million.
The company reduced total indebtedness to $12.2 million from $25.4 million and received the final $10.7 million payment from Companion Spine. It raised full-year 2026 revenue guidance to $101–$105 million and entered an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows, adding Dilon’s U.S. sales team.
Xtant Medical (NYSE American: XTNT) will release first quarter 2026 financial results for the period ended March 31, 2026, before market open on Wednesday, May 13, 2026. Management will host a conference call at 8:30 AM ET that day; a replay will be posted on the company's investor site.
Conference dial-ins, passcode, webcast link, and replay location are provided for investors and analysts to access the live presentation and subsequent recording.
Xtant Medical (NYSE American: XTNT) announced the commercial launch of Trivium™ Shaped on May 6, 2026, an extension of the Trivium bone graft portfolio offering pre-shaped, ready-to-use forms (boats and strips) for surgical use.
Trivium Shaped builds on the April 2025 sculptable format, uses PureLoc™ automated DBM milling to produce elongated cortical fibers, and is available through Xtant's nationwide independent agent distribution network.
Xtant Medical (NYSE:XTNT) acquired exclusive U.S. distribution rights to Dilon Technologies' HEMOBLAST® Bellows, a pre-loaded hemostatic powder for minimal to moderate surgical bleeding. Xtant will integrate Dilon's approximately 20-person U.S. sales team and aims to expand penetration of an estimated $2.0 billion global hemostatic market.
HEMOBLAST contains collagen, human thrombin, and bovine chondroitin sulfate and requires no prep. Xtant plans to update its full-year 2026 financial guidance when reporting Q1 2026 results.
Xtant Medical (NYSE American: XTNT) announced support for the Threshold of Life Memorial, an outdoor tribute to organ, eye, and tissue donors planned for the Montana State Capitol grounds in Helena. The project is approved for design and location with targeted completion in Summer 2028.
The memorial will feature symbolic elements (water, circular structure, pollinator garden), be funded entirely by private support, and list the Helena Area Community Foundation as fiscal sponsor. The initiative highlights Montana's high donor registration rate of 86%.
Xtant Medical (NYSE:XTNT) reported full-year 2025 revenue of $133.9M, up ~14% year-over-year, with net income of $5.0M and adjusted EBITDA of $16.3M. Cash from operations was $12.5M and cash on hand was $17.3M as of Dec 31, 2025, excluding $10.5M received subsequent to year-end.
The company completed the sale of Coflex, CoFix and international hardware to Companion Spine for $21.4M cash, launched nanOss Strata and CollagenX, and issued 2026 revenue guidance of $95M–$99M.